Control Bionics Ltd. (AU:CBL)
ASX:CBL
Want to see AU:CBL full AI Analyst Report?
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.10
Previous CloseN/A
Volume65.91K
Average Volume (3M)173.99K
Market Cap
AU$35.84M
Enterprise ValueAU$15.09M
Total Cash (Recent Filing)AU$3.06M
Total Debt (Recent Filing)AU$258.10K
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit revenue growth demonstrates durable end-market demand for the company’s products. Over 2–6 months this supports scaling of operations and gives management runway to improve unit economics and invest in commercialization to drive longer-term profitability.
Conservative LeverageA low debt load and strong equity financing reduce solvency risk and preserve strategic flexibility. This conservative capital structure makes it easier to raise growth capital if needed, and lowers bankruptcy risk while management focuses on scaling and product development.
Focused Assistive-Technology BusinessA clear niche in assistive tech and human–machine interfaces aligns the company with structural healthcare and accessibility trends. Specialized products and clinical use cases create durable demand and potential stickiness with institutional customers over the medium term.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow weakens liquidity and forces dependence on external financing. Over several months this can constrain R&D, commercialization, and customer support initiatives, and increase dilution or refinancing risk if cash conversion does not improve.
Persistent Net Losses And Weak ProfitabilityOngoing net losses indicate the company has yet to convert revenue into sustainable profits. Weak EBIT margins limit internal funding for growth, strain operating levers, and mean management must deliver structural margin improvements to achieve long-term viability.
Negative Return On EquityA negative ROE shows deployed capital has not produced shareholder returns, signaling inefficient capital allocation. Over the medium term this can impair investor confidence and raise the cost of capital, making future funding more onerous if operational performance doesn't improve.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$35.84M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 411,961,880 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
-98.14%
Trailing 12-Months
Asset Growth
12.36%
Trailing 12-Months
Company Description
Control Bionics Ltd.
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
Technical Analysis
Options Prices
Currently, No data available
---